AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.35 USD
+0.06 (2.62%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.34 -0.01 (-0.43%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACIU 2.35 +0.06(2.62%)
Will ACIU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACIU
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
5 Small-Cap Stocks to Play the January Effect
Other News for ACIU
CALM, PLAY and VNDA are among after hour movers
CALM,PLAY and VNDA are among after hour movers
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Buy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated Approval
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023